{"title":"[在医院使用新型氟喹诺酮类药物的经济考虑]。","authors":"F Maggiolo, G Pellegata, G Marchetti, F Suter","doi":"","DOIUrl":null,"url":null,"abstract":"<p><p>Availability of new fluorinated quinolones offers, in the hospital setting, the opportunity to change, in many circumstances, parenteral therapy with oral administration of drugs. This possibility must always depend upon medical considerations, but permits a cost-containment policy with a drastic reduction of hospitalization and therapeutic costs. As far as the latter is concerned a daily cost reduction of 70000-16000 lire is foreseeable.</p>","PeriodicalId":12704,"journal":{"name":"Giornale italiano di chemioterapia","volume":"36 1-3","pages":"101-4"},"PeriodicalIF":0.0000,"publicationDate":"1989-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"[Economic considerations on the use of the new fluoroquinolones in the hospital setting].\",\"authors\":\"F Maggiolo, G Pellegata, G Marchetti, F Suter\",\"doi\":\"\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p>Availability of new fluorinated quinolones offers, in the hospital setting, the opportunity to change, in many circumstances, parenteral therapy with oral administration of drugs. This possibility must always depend upon medical considerations, but permits a cost-containment policy with a drastic reduction of hospitalization and therapeutic costs. As far as the latter is concerned a daily cost reduction of 70000-16000 lire is foreseeable.</p>\",\"PeriodicalId\":12704,\"journal\":{\"name\":\"Giornale italiano di chemioterapia\",\"volume\":\"36 1-3\",\"pages\":\"101-4\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"1989-01-01\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Giornale italiano di chemioterapia\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Giornale italiano di chemioterapia","FirstCategoryId":"1085","ListUrlMain":"","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
[Economic considerations on the use of the new fluoroquinolones in the hospital setting].
Availability of new fluorinated quinolones offers, in the hospital setting, the opportunity to change, in many circumstances, parenteral therapy with oral administration of drugs. This possibility must always depend upon medical considerations, but permits a cost-containment policy with a drastic reduction of hospitalization and therapeutic costs. As far as the latter is concerned a daily cost reduction of 70000-16000 lire is foreseeable.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
